Clínica e Investigación en Arteriosclerosis (English Edition)最新文献

Lysyl oxidase expression in smooth muscle cells determines the level of intima calcification in hypercholesterolemia-induced atherosclerosis 平滑肌细胞中赖氨酸氧化酶的表达决定了高胆固醇血症诱发的动脉粥样硬化的内膜钙化水平

Clínica e Investigación en Arteriosclerosis (English Edition)

Pub Date : 2024-09-01 DOI: 10.1016/j.artere.2024.09.001

Carme Ballester-Servera , Judith Alonso , Manel Taurón , Noemí Rotllán , Cristina Rodríguez , José Martínez-González

Introduction

Cardiovascular calcification is an important public health issue with an unmeet therapeutic need. We had previously shown that lysyl oxidase (LOX) activity critically influences vascular wall smooth muscle cells (VSMCs) and valvular interstitial cells (VICs) calcification by affecting extracellular matrix remodeling. We have delved into the participation of LOX in atherosclerosis and vascular calcification, as well as in the mineralization of the aortic valve.

Methods

Immunohistochemical and expression studies were carried out in human atherosclerotic lesions and experimental models, valves from patients with aortic stenosis, VICs, and in a genetically modified mouse model that overexpresses LOX in CMLV (TgLOX^CMLV). Hyperlipemia and atherosclerosis was induced in mice through the administration of adeno-associated viruses encoding a PCSK9 mutated form (AAV-PCSK9^D374Y) combined with an atherogenic diet.

Results

LOX expression is increased in the neointimal layer of atherosclerotic lesions from human coronary arteries and in VSMC-rich regions of atheromas developed both in the brachiocephalic artery of control (C57BL/6 J) animals transduced with PCSK9^D374Y and in the aortic root of ApoE^−/− mice. In TgLOX^CMLV mice, PCSK9^D374Y transduction did not significantly alter the enhanced aortic expression of genes involved in matrix remodeling, inflammation, oxidative stress and osteoblastic differentiation. Likewise, LOX transgenesis did not alter the size or lipid content of atherosclerotic lesions in the aortic arch, brachiocephalic artery and aortic root, but exacerbated calcification. Among lysyl oxidase isoenzymes, LOX is the most expressed member of this family in highly calcified human valves, colocalizing with RUNX2 in VICs. The lower calcium deposition and decreased RUNX2 levels triggered by the overexpression of the nuclear receptor NOR-1 in VICs was associated with a reduction in LOX.

Conclusions

Our results show that LOX expression is increased in atherosclerotic lesions, and that overexpression of this enzyme in VSMC does not affect the size of the atheroma or its lipid content, but it does affect its degree of calcification. Further, these data suggest that the decrease in calcification driven by NOR-1 in VICs would involve a reduction in LOX. These evidences support the interest of LOX as a therapeutic target in cardiovascular calcification.

导言：心血管钙化是一个重要的公共卫生问题，但治疗需求尚未得到满足。我们之前已经证明，赖氨酰氧化酶（LOX）活性通过影响细胞外基质重塑，对血管壁平滑肌细胞（VSMC）和瓣膜间质细胞（VIC）的钙化产生关键影响。我们对 LOX 参与动脉粥样硬化和血管钙化以及主动脉瓣矿化的情况进行了深入研究。方法在人类动脉粥样硬化病变和实验模型、主动脉瓣狭窄患者的瓣膜、VICs 以及在 CMLV 中过表达 LOX 的转基因小鼠模型（TgLOXCMLV）中进行了免疫组织化学和表达研究。通过给小鼠注射编码 PCSK9 突变形式的腺相关病毒（AAV-PCSK9D374Y）并结合致动脉粥样硬化饮食，诱导小鼠出现高脂血症和动脉粥样硬化。结果在用 PCSK9D374Y 转导的对照组（C57BL/6 J）动物的肱动脉和载脂蛋白E/-小鼠的主动脉根部形成的动脉粥样硬化病变的新内膜层和血管内皮细胞丰富的区域，LOX 的表达都有所增加。在 TgLOXCMLV 小鼠中，PCSK9D374Y 转导并未显著改变基质重塑、炎症、氧化应激和成骨细胞分化相关基因在主动脉中的表达。同样，LOX 转基因也不会改变主动脉弓、肱动脉和主动脉根部动脉粥样硬化病变的大小或脂质含量，但会加剧钙化。在赖氨酰氧化酶同工酶中，LOX是高度钙化的人体瓣膜中表达最多的同工酶家族成员，与RUNX2共定位在VICs中。结论我们的研究结果表明，LOX 在动脉粥样硬化病变中的表达量增加，这种酶在 VSMC 中的过度表达不会影响动脉粥样斑块的大小或其脂质含量，但会影响其钙化程度。此外，这些数据还表明，NOR-1 在血管内皮细胞中驱动的钙化减少将涉及 LOX 的减少。这些证据支持将 LOX 作为心血管钙化的治疗靶点。

{"title":"Lysyl oxidase expression in smooth muscle cells determines the level of intima calcification in hypercholesterolemia-induced atherosclerosis","authors":"Carme Ballester-Servera , Judith Alonso , Manel Taurón , Noemí Rotllán , Cristina Rodríguez , José Martínez-González","doi":"10.1016/j.artere.2024.09.001","DOIUrl":"10.1016/j.artere.2024.09.001","url":null,"abstract":"<div><h3>Introduction</h3><div>Cardiovascular calcification is an important public health issue with an unmeet therapeutic need. We had previously shown that lysyl oxidase (LOX) activity critically influences vascular wall smooth muscle cells (VSMCs) and valvular interstitial cells (VICs) calcification by affecting extracellular matrix remodeling. We have delved into the participation of LOX in atherosclerosis and vascular calcification, as well as in the mineralization of the aortic valve.</div></div><div><h3>Methods</h3><div>Immunohistochemical and expression studies were carried out in human atherosclerotic lesions and experimental models, valves from patients with aortic stenosis, VICs, and in a genetically modified mouse model that overexpresses LOX in CMLV (TgLOX<sup>CMLV</sup>). Hyperlipemia and atherosclerosis was induced in mice through the administration of adeno-associated viruses encoding a PCSK9 mutated form (AAV-PCSK9<sup>D374Y</sup>) combined with an atherogenic diet.</div></div><div><h3>Results</h3><div>LOX expression is increased in the neointimal layer of atherosclerotic lesions from human coronary arteries and in VSMC-rich regions of atheromas developed both in the brachiocephalic artery of control (C57BL/6 J) animals transduced with PCSK9<sup>D374Y</sup> and in the aortic root of ApoE<sup>−/−</sup> mice. In TgLOX<sup>CMLV</sup> mice, PCSK9<sup>D374Y</sup> transduction did not significantly alter the enhanced aortic expression of genes involved in matrix remodeling, inflammation, oxidative stress and osteoblastic differentiation. Likewise, LOX transgenesis did not alter the size or lipid content of atherosclerotic lesions in the aortic arch, brachiocephalic artery and aortic root, but exacerbated calcification. Among lysyl oxidase isoenzymes, LOX is the most expressed member of this family in highly calcified human valves, colocalizing with RUNX2 in VICs. The lower calcium deposition and decreased RUNX2 levels triggered by the overexpression of the nuclear receptor NOR-1 in VICs was associated with a reduction in LOX.</div></div><div><h3>Conclusions</h3><div>Our results show that LOX expression is increased in atherosclerotic lesions, and that overexpression of this enzyme in VSMC does not affect the size of the atheroma or its lipid content, but it does affect its degree of calcification. Further, these data suggest that the decrease in calcification driven by NOR-1 in VICs would involve a reduction in LOX. These evidences support the interest of LOX as a therapeutic target in cardiovascular calcification.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"36 5","pages":"Pages 286-298"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142418539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early detection of severe hypertriglyceridemia using teleconsultation in a clinical laboratory setting 在临床实验室环境中利用远程会诊早期发现严重的高甘油三酯血症

Clínica e Investigación en Arteriosclerosis (English Edition)

Pub Date : 2024-09-01 DOI: 10.1016/j.artere.2024.09.005

Teresa Arrobas-Velilla , María José Ariza , Miguel Ángel Rico-Corral , Pedro Valdivielso

Background

Teleconsultation in the context of clinical laboratories is a valuable tool for the early detection of dyslipidemia and prevention of cardiovascular risk. Here, we describe a patient who was referred to the Lipid Unit of the Virgen Macarena Hospital due to an alert for severe hypertriglyceridemia through its teleconsultation program.

Case presentation

A comprehensive clinical and biochemical study of the patient was carried out, and genetic testing was performed on the patient and his family. The proband and his family showed mild to severe hypertriglyceridemia and various secondary factors, together with a genetic background associated with a triglyceride-raising effect.

Conclusion

This extensive study has identified a family at high risk of cardiovascular disease and acute pancreatitis. These findings can help maximize lifestyle changes and improve the clinical management of their dyslipidemia.

背景临床实验室的远程会诊是早期发现血脂异常和预防心血管风险的重要工具。在此，我们描述了一名通过远程会诊项目被转诊到圣玛卡莱娜医院血脂科的患者。病例介绍对患者进行了全面的临床和生化研究，并对患者及其家人进行了基因检测。原发性高甘油三酯血症及其家人表现出轻度至重度高甘油三酯血症和各种继发性因素，以及与甘油三酯升高效应相关的遗传背景。这些发现有助于最大限度地改变生活方式，改善血脂异常的临床治疗。

引用次数: 0

Update on cardiac imaging: A critical analysis 心脏成像的最新进展：重要分析

Clínica e Investigación en Arteriosclerosis (English Edition)

Pub Date : 2024-09-01 DOI: 10.1016/j.artere.2024.09.006

Halia Shah , Samina Alim , Sonia Akther , Mahnoor Irfan , Jamolbi Rahmatova , Aneesa Arshad , Charlene Hui Ping Kok , Syeda Anum Zahra

Imaging is instrumental in diagnosing and directing the management of atherosclerosis. In 1958 the first diagnostic coronary angiography (CA) was performed, and since then further development has led to new methods such as coronary CT angiography (CTA), optical coherence tomography (OCT), positron tomography (PET), and intravascular ultrasound (IVUS). Currently, CA remains powerful for visualizing coronary arteries; however, recent studies show the benefits of using other non-invasive techniques. This review identifies optimum imaging techniques for diagnosing and monitoring plaque stability. This becomes even direr now, given the rapidly rising incidence of atherosclerosis in society today. Many acute coronary events, including acute myocardial infarctions and sudden deaths, are attributable to plaque rupture. Although fatal, these events can be preventable. We discuss the factors affecting plaque integrity, such as increased inflammation, medications like statins, and increased lipid content. Some of these precipitating factors are identifiable through imaging. However, we also highlight significant complications arising in some modalities; in CA this can include ventricular arrhythmia and even death. Extending this, we elucidated from the literature that risk can also vary based on the location of arteries and their plaques. Promisingly, there are less invasive methods being trialled for assessing plaque stability, such as Cardiac Magnetic Resonance Imaging (CMR), which is already in use for other cardiac diseases like cardiomyopathies. Therefore, future research focusing on using imaging modalities in conjunction may be sensible, to bridge between the effectiveness of modalities, at the expense of increased complications, and vice versa.

成像技术在诊断和指导动脉粥样硬化的治疗方面发挥着重要作用。1958 年，第一例诊断性冠状动脉造影术（CA）问世，此后，冠状动脉 CT 血管造影术（CTA）、光学相干断层扫描（OCT）、正电子断层扫描（PET）和血管内超声波（IVUS）等新方法不断发展。目前，CA 仍是冠状动脉可视化的有力手段；但最近的研究表明，使用其他无创技术也有好处。本综述确定了诊断和监测斑块稳定性的最佳成像技术。鉴于当今社会动脉粥样硬化的发病率急剧上升，这一问题变得更加紧迫。许多急性冠状动脉事件，包括急性心肌梗死和猝死，都可归因于斑块破裂。虽然这些事件是致命的，但却是可以预防的。我们将讨论影响斑块完整性的因素，如炎症加剧、他汀类药物等药物以及脂质含量增加。其中一些诱发因素可以通过影像学识别。不过，我们也强调了某些模式下出现的重大并发症；在 CA 中，这可能包括室性心律失常甚至死亡。在此基础上，我们从文献中阐明，风险也会因动脉及其斑块的位置而异。令人欣慰的是，目前正在试用一些侵入性较小的方法来评估斑块的稳定性，如心脏磁共振成像（CMR），它已被用于其他心脏疾病，如心肌病。因此，未来的研究重点可能是结合使用成像模式，以增加并发症为代价在各种模式的有效性之间架起一座桥梁，反之亦然。

{"title":"Update on cardiac imaging: A critical analysis","authors":"Halia Shah , Samina Alim , Sonia Akther , Mahnoor Irfan , Jamolbi Rahmatova , Aneesa Arshad , Charlene Hui Ping Kok , Syeda Anum Zahra","doi":"10.1016/j.artere.2024.09.006","DOIUrl":"10.1016/j.artere.2024.09.006","url":null,"abstract":"<div><div>Imaging is instrumental in diagnosing and directing the management of atherosclerosis. In 1958 the first diagnostic coronary angiography (CA) was performed, and since then further development has led to new methods such as coronary CT angiography (CTA), optical coherence tomography (OCT), positron tomography (PET), and intravascular ultrasound (IVUS). Currently, CA remains powerful for visualizing coronary arteries; however, recent studies show the benefits of using other non-invasive techniques. This review identifies optimum imaging techniques for diagnosing and monitoring plaque stability. This becomes even direr now, given the rapidly rising incidence of atherosclerosis in society today. Many acute coronary events, including acute myocardial infarctions and sudden deaths, are attributable to plaque rupture. Although fatal, these events can be preventable. We discuss the factors affecting plaque integrity, such as increased inflammation, medications like statins, and increased lipid content. Some of these precipitating factors are identifiable through imaging. However, we also highlight significant complications arising in some modalities; in CA this can include ventricular arrhythmia and even death. Extending this, we elucidated from the literature that risk can also vary based on the location of arteries and their plaques. Promisingly, there are less invasive methods being trialled for assessing plaque stability, such as Cardiac Magnetic Resonance Imaging (CMR), which is already in use for other cardiac diseases like cardiomyopathies. Therefore, future research focusing on using imaging modalities in conjunction may be sensible, to bridge between the effectiveness of modalities, at the expense of increased complications, and vice versa.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"36 5","pages":"Pages 304-313"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142418542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lipoprotein (a) is a predictor of non-achievement of LDL-C goals in patients with chronic heart disease 脂蛋白（a）是慢性心脏病患者无法达到低密度脂蛋白胆固醇目标的预测因子

Clínica e Investigación en Arteriosclerosis (English Edition)

Pub Date : 2024-09-01 DOI: 10.1016/j.artere.2024.09.002

José Javier Gómez-Barrado, Paula Gómez-Turégano, María Beltrán Moreno, Ana Isabel Fernández-Chamorro, Benjamín Roque Rodríguez, Zineb Kounka

Introduction and objectives

Lipoprotein (a) [Lp(a)] concentration influences serum low-density lipoprotein cholesterol (LDL-C) levels. How it influences the achievement of LDL-C targets established in the guidelines is not well studied. Our aim was to know the prevalence of elevated Lp(a) levels in patients with coronary artery disease (CAD), and to assess its influence on the achievement of LDL-C targets.

Method

We conducted a cross-sectional study in a Cardiology department in Spain. A total of 870 patients with stable CAD had their lipid profile determined, including Lp(a). Patients were stratified into two groups according to Lp(a) >50 mg/dL and Lp(a) ≤50 mg/dL. The association of Lp(a) >50 mg/dL with achievement of LDL-C targets was assessed by logistic regression analysis.

Results

The prevalence of Lp(a) >50 mg/dL was 30.8%. Patients with Lp(a) >50 mg/dL had higher baseline (142.30 ± 47.54 mg/dL vs 130.47 ± 40.75 mg/dL; p = 0.0001) and current (72.91 ± 26.44 mg/dL vs 64.72 ± 25.30 mg/dL; p = 0.0001), despite the fact that they were treated with more high-potency statins (77.2% vs 70.9%; p = 0.058) and more combination lipid-lowering therapy (LLT) (37.7% vs 25.7%; p = 0.001). The proportion of patients achieving target LDL-C was lower in those with Lp(a) >50 mg/dL. Independent predictors of having elevated Lp(a) levels >50 mg/dL were the use of high-potency statins (OR 1.5; 95% CI 1.08−2.14), combination LLT with ezetimibe (OR 2.0; 95% CI 1.45−2.73) and failure to achieve a LDL-C ≤55 mg/dL (OR 2.3; 95% CI 1.63−3.23).

Conclusions

Elevated Lp(a) levels influence LDL-C levels and hinder the achievement of targets in patients at very high cardiovascular risk. New drugs that act directly on Lp(a) are needed in these patients.

导言和目的脂蛋白（a）[Lp（a）]浓度影响血清低密度脂蛋白胆固醇（LDL-C）水平。它如何影响实现指南中规定的低密度脂蛋白胆固醇目标尚未得到充分研究。我们的目的是了解冠状动脉疾病（CAD）患者 Lp（a）水平升高的发生率，并评估其对实现低密度脂蛋白胆固醇目标的影响。共有 870 名稳定型冠状动脉疾病患者接受了包括脂蛋白（a）在内的血脂测定。根据脂蛋白（a）>50 毫克/分升和脂蛋白（a）≤50 毫克/分升将患者分为两组。结果 Lp(a) >50 mg/dL 的患病率为 30.8%。Lp(a) >50 mg/dL 患者的基线（142.30 ± 47.54 mg/dL vs 130.47 ± 40.75 mg/dL；p = 0.0001）和当前（72.91 ± 26.44 mg/dL vs 64.72 ± 25.30 mg/dL; p = 0.0001），尽管他们接受了更多的高效他汀类药物治疗（77.2% vs 70.9%; p = 0.058）和更多的联合降脂治疗（LLT）（37.7% vs 25.7%; p = 0.001）。Lp（a）为 50 mg/dL 的患者达到目标 LDL-C 的比例较低。Lp(a)水平升高>50 mg/dL的独立预测因素是使用高效他汀类药物（OR 1.5；95% CI 1.08-2.14）、与依折麦布联合LLT（OR 2.0；95% CI 1.45-2.73）以及未能达到低密度脂蛋白胆固醇目标值。结论Lp（a）水平升高会影响低密度脂蛋白胆固醇（LDL-C）水平，并阻碍心血管风险极高的患者达到目标。这些患者需要能直接作用于脂蛋白（a）的新药。

{"title":"Lipoprotein (a) is a predictor of non-achievement of LDL-C goals in patients with chronic heart disease","authors":"José Javier Gómez-Barrado, Paula Gómez-Turégano, María Beltrán Moreno, Ana Isabel Fernández-Chamorro, Benjamín Roque Rodríguez, Zineb Kounka","doi":"10.1016/j.artere.2024.09.002","DOIUrl":"10.1016/j.artere.2024.09.002","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Lipoprotein (a) [Lp(a)] concentration influences serum low-density lipoprotein cholesterol (LDL-C) levels. How it influences the achievement of LDL-C targets established in the guidelines is not well studied. Our aim was to know the prevalence of elevated Lp(a) levels in patients with coronary artery disease (CAD), and to assess its influence on the achievement of LDL-C targets.</div></div><div><h3>Method</h3><div>We conducted a cross-sectional study in a Cardiology department in Spain. A total of 870 patients with stable CAD had their lipid profile determined, including Lp(a). Patients were stratified into two groups according to Lp(a) >50 mg/dL and Lp(a) ≤50 mg/dL. The association of Lp(a) >50 mg/dL with achievement of LDL-C targets was assessed by logistic regression analysis.</div></div><div><h3>Results</h3><div>The prevalence of Lp(a) >50 mg/dL was 30.8%. Patients with Lp(a) >50 mg/dL had higher baseline (142.30 ± 47.54 mg/dL vs 130.47 ± 40.75 mg/dL; p = 0.0001) and current (72.91 ± 26.44 mg/dL vs 64.72 ± 25.30 mg/dL; p = 0.0001), despite the fact that they were treated with more high-potency statins (77.2% vs 70.9%; p = 0.058) and more combination lipid-lowering therapy (LLT) (37.7% vs 25.7%; p = 0.001). The proportion of patients achieving target LDL-C was lower in those with Lp(a) >50 mg/dL. Independent predictors of having elevated Lp(a) levels >50 mg/dL were the use of high-potency statins (OR 1.5; 95% CI 1.08−2.14), combination LLT with ezetimibe (OR 2.0; 95% CI 1.45−2.73) and failure to achieve a LDL-C ≤55 mg/dL (OR 2.3; 95% CI 1.63−3.23).</div></div><div><h3>Conclusions</h3><div>Elevated Lp(a) levels influence LDL-C levels and hinder the achievement of targets in patients at very high cardiovascular risk. New drugs that act directly on Lp(a) are needed in these patients.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"36 5","pages":"Pages 278-285"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142418538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The long, winding and favourable road of Clínica e Investigación en Arteriosclerosis 漫长、曲折而又有利的动脉硬化临床与研究之路

Clínica e Investigación en Arteriosclerosis (English Edition)

Pub Date : 2024-09-01 DOI: 10.1016/j.artere.2024.09.003

X. Pintó, C. Lahoz, J. Ribalta

引用次数: 0

Relationship between dietary oxidative balance score, anthropometric measurements and socioeconomic factors in women at low risk of cardiovascular disease 心血管疾病低风险女性的膳食氧化平衡评分、人体测量和社会经济因素之间的关系

Clínica e Investigación en Arteriosclerosis (English Edition)

Pub Date : 2024-09-01 DOI: 10.1016/j.artere.2024.09.004

Sanem Güven , Aylin Seylam Küşümler

Introduction

The aim of this study was to investigate the relationship between the dietary oxidative balance score (OBS), an indicator of oxidative stress, anthropometric measures and socioeconomic factors in women at low risk of cardiovascular disease.

Methods

The participants’ 3-day dietary intake, demographic information, anthropometric measurements and blood pressure values were recorded, and the Framingham Risk Score (FRS) and OBS values were determined. Oxidative balance score consists of prooxidant and antioxidant scores. Prooxidant scores were calculated from red meat consumption, total iron and polyunsaturated fatty acid intake, alcohol and cigarette consumption parameters, while antioxidant scores were calculated by assessing cruciferous consumption, dietary total vitamin C, vitamin E, β-carotene, β-cryptoxanthin, β-carotene, β-cryptoxanthin, lycopene, lutein + zeaxanthin and selenium intake.

Results

A total of 145 women were included in the study. Education level was associated with anthropometric measurements, income status with antioxidant and prooxidant scores, and exercise status with OBS (p < 0.05). Weight, waist, hip, BMI, waist/hip, and waist/height ratio were significantly lower in subjects with low prooxidant score (p < 0.05); there was no significant relationship between age, systolic, diastolic, FRS (p > 0.05).

Conclusion

The study, conducted in healthy women, showed that dietary oxidative balance scoring is promising in preventing the development of CVD and reducing the burden of disease, and that prospective cohort studies should be conducted in this area.

方法记录参与者 3 天的饮食摄入量、人口统计学信息、人体测量值和血压值，并确定弗雷明汉风险评分（FRS）和氧化平衡评分值。氧化平衡评分由原氧化剂评分和抗氧化剂评分组成。前氧化剂得分根据红肉摄入量、总铁和多不饱和脂肪酸摄入量、酒精和香烟摄入量参数计算，而抗氧化剂得分则通过评估十字花科植物摄入量、膳食总维生素 C、维生素 E、β-胡萝卜素、β-隐黄素、β-胡萝卜素、β-隐黄素、番茄红素、叶黄素 + 玉米黄质和硒摄入量计算。教育水平与人体测量相关，收入状况与抗氧化剂和原氧化剂得分相关，运动状况与 OBS 相关（p < 0.05）。体重、腰围、臀围、体重指数（BMI）、腰围/臀围和腰围/身高比在低抗氧化剂评分的受试者中明显较低（p <0.05）；年龄、收缩压、舒张压、FRS 之间无明显关系（p >0.05）。

{"title":"Relationship between dietary oxidative balance score, anthropometric measurements and socioeconomic factors in women at low risk of cardiovascular disease","authors":"Sanem Güven , Aylin Seylam Küşümler","doi":"10.1016/j.artere.2024.09.004","DOIUrl":"10.1016/j.artere.2024.09.004","url":null,"abstract":"<div><h3>Introduction</h3><div>The aim of this study was to investigate the relationship between the dietary oxidative balance score (OBS), an indicator of oxidative stress, anthropometric measures and socioeconomic factors in women at low risk of cardiovascular disease.</div></div><div><h3>Methods</h3><div>The participants’ 3-day dietary intake, demographic information, anthropometric measurements and blood pressure values were recorded, and the Framingham Risk Score (FRS) and OBS values were determined. Oxidative balance score consists of prooxidant and antioxidant scores. Prooxidant scores were calculated from red meat consumption, total iron and polyunsaturated fatty acid intake, alcohol and cigarette consumption parameters, while antioxidant scores were calculated by assessing cruciferous consumption, dietary total vitamin C, vitamin E, β-carotene, β-cryptoxanthin, β-carotene, β-cryptoxanthin, lycopene, lutein+zeaxanthin and selenium intake.</div></div><div><h3>Results</h3><div>A total of 145 women were included in the study. Education level was associated with anthropometric measurements, income status with antioxidant and prooxidant scores, and exercise status with OBS (<em>p</em>  <0.05); there was no significant relationship between age, systolic, diastolic, FRS (<em>p</em>  <!-->0.05).</div></div><div><h3>Conclusion</h3><div>The study, conducted in healthy women, showed that dietary oxidative balance scoring is promising in preventing the development of CVD and reducing the burden of disease, and that prospective cohort studies should be conducted in this area.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"36 5","pages":"Pages 269-277"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142418537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Obstructive sleep apnea and cardiovascular risk 阻塞性睡眠呼吸暂停与心血管风险

Clínica e Investigación en Arteriosclerosis (English Edition)

Pub Date : 2024-07-01 DOI: 10.1016/j.artere.2024.07.003

Gerard Torres , Manuel Sánchez de la Torre , Lucia Pinilla , Ferran Barbé

Patients with obstructive sleep apnea (OSA) experience repetitive episodes of upper airway obstruction due to recurrent collapse during sleep. This leads to intermittent hypoxia episodes, which, through complex pathophysiological mechanisms, trigger sympathetic overactivation, endothelial dysfunction, hypercoagulation, and metabolic dysregulation. Consequently, other cardiovascular risk factors such as hypertension, metabolic syndrome, and diabetes are induced. Furthermore, this enhances target organ damage, affecting the heart, arteries, and kidneys, leading to an increased risk of cardiovascular morbidity and mortality. Among the various treatments for OSA, Continuous Positive Airway Pressure (CPAP) has been extensively studied. To date, this treatment has shown mild benefits in reducing blood pressure, particularly noticeable in patients with resistant hypertension. Furthermore, CPAP treatment appears to reduce cardiovascular events, both in primary and secondary prevention, though this benefit is limited to individuals with good compliance (CPAP use ≥ 4 h/night). Future research perspectives in OSA seem to focus on identifying patients in whom the condition significantly influences cardiovascular risk, thus determining those who would benefit the most from treatment in the reduction of cardiovascular risk.

阻塞性睡眠呼吸暂停（OSA）患者由于在睡眠过程中反复发生塌陷，导致上气道阻塞反复发作。这导致间歇性缺氧发作，通过复杂的病理生理机制，引发交感神经过度激活、内皮功能障碍、高凝状态和代谢失调。因此，会诱发其他心血管风险因素，如高血压、代谢综合征和糖尿病。此外，这会加重靶器官损伤，影响心脏、动脉和肾脏，导致心血管疾病发病率和死亡率风险增加。在治疗 OSA 的各种方法中，持续气道正压（CPAP）已被广泛研究。迄今为止，这种治疗方法在降低血压方面显示出轻微的益处，尤其是在耐药性高血压患者中效果明显。此外，CPAP 治疗似乎还能减少心血管事件的发生，无论是一级预防还是二级预防，不过这种益处仅限于依从性良好的患者（CPAP 使用时间≥ 4 小时/晚）。未来对 OSA 的研究似乎将重点放在识别对心血管风险有重大影响的患者上，从而确定哪些患者能从降低心血管风险的治疗中获益最多。

{"title":"Obstructive sleep apnea and cardiovascular risk","authors":"Gerard Torres , Manuel Sánchez de la Torre , Lucia Pinilla , Ferran Barbé","doi":"10.1016/j.artere.2024.07.003","DOIUrl":"10.1016/j.artere.2024.07.003","url":null,"abstract":"<div><p>Patients with obstructive sleep apnea (OSA) experience repetitive episodes of upper airway obstruction due to recurrent collapse during sleep. This leads to intermittent hypoxia episodes, which, through complex pathophysiological mechanisms, trigger sympathetic overactivation, endothelial dysfunction, hypercoagulation, and metabolic dysregulation. Consequently, other cardiovascular risk factors such as hypertension, metabolic syndrome, and diabetes are induced. Furthermore, this enhances target organ damage, affecting the heart, arteries, and kidneys, leading to an increased risk of cardiovascular morbidity and mortality. Among the various treatments for OSA, Continuous Positive Airway Pressure (CPAP) has been extensively studied. To date, this treatment has shown mild benefits in reducing blood pressure, particularly noticeable in patients with resistant hypertension. Furthermore, CPAP treatment appears to reduce cardiovascular events, both in primary and secondary prevention, though this benefit is limited to individuals with good compliance (CPAP use ≥4h/night). Future research perspectives in OSA seem to focus on identifying patients in whom the condition significantly influences cardiovascular risk, thus determining those who would benefit the most from treatment in the reduction of cardiovascular risk.</p></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"36 4","pages":"Pages 234-242"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141693400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Consensus on lipoprotein(a) of the Spanish Society of Arteriosclerosis. Literature review and recommendations for clinical practice 西班牙动脉硬化学会脂蛋白（a）共识。文献综述和临床实践建议

Clínica e Investigación en Arteriosclerosis (English Edition)

Pub Date : 2024-07-01 DOI: 10.1016/j.artere.2024.07.008

Javier Delgado-Lista , Jose M. Mostaza , Teresa Arrobas-Velilla , Francisco Blanco-Vaca , Luis Masana , Juan Pedro-Botet , Pablo Perez-Martinez , Fernando Civeira , Jose I. Cuende-Melero , Jose J. Gomez-Barrado , Carlos Lahoz , Xavier Pintó , Manuel Suarez-Tembra , Jose Lopez-Miranda , Carlos Guijarro

The irruption of lipoprotein(a) (Lp(a)) in the study of cardiovascular risk factors is perhaps, together with the discovery and use of proprotein convertase subtilisin/kexin type 9 (iPCSK9) inhibitor drugs, the greatest novelty in the field for decades. Lp(a) concentration (especially very high levels) has an undeniable association with certain cardiovascular complications, such as atherosclerotic vascular disease (AVD) and aortic stenosis. However, there are several current limitations to both establishing epidemiological associations and specific pharmacological treatment. Firstly, the measurement of Lp(a) is highly dependent on the test used, mainly because of the characteristics of the molecule. Secondly, Lp(a) concentration is more than 80% genetically determined, so that, unlike other cardiovascular risk factors, it cannot be regulated by lifestyle changes. Finally, although there are many promising clinical trials with specific drugs to reduce Lp(a), currently only iPCSK9 (limited for use because of its cost) significantly reduces Lp(a).

However, and in line with other scientific societies, the SEA considers that, with the aim of increasing knowledge about the contribution of Lp(a) to cardiovascular risk, it is relevant to produce a document containing the current status of the subject, recommendations for the control of global cardiovascular risk in people with elevated Lp(a) and recommendations on the therapeutic approach to patients with elevated Lp(a).

脂蛋白（a）（Lp(a)）在心血管风险因素研究中的应用，可能是几十年来该领域最大的新发现，此外还有丙蛋白转化酶枯草酶/kexin 9 型（iPCSK9）抑制剂药物的发现和使用。脂蛋白（a）浓度（尤其是极高浓度）与某些心血管并发症（如动脉粥样硬化性血管疾病（AVD）和主动脉狭窄）有着不可否认的联系。然而，目前在确定流行病学关联和特定药物治疗方面都存在一些局限性。首先，脂蛋白（a）的测量高度依赖于所使用的检测方法，这主要是因为该分子的特性。其次，脂蛋白（a）的浓度 80% 以上是由基因决定的，因此，与其他心血管风险因素不同，脂蛋白（a）无法通过改变生活方式来调节。最后，尽管有许多临床试验表明，使用特定药物来降低脂蛋白（a）是有希望的，但目前只有 iPCSK9（因其成本而使用受限）能显著降低脂蛋白（a）。然而，与其他科学协会一样，东南欧医学协会认为，为了增加人们对脂蛋白（a）导致心血管风险的了解，有必要编写一份文件，介绍该主题的现状、控制脂蛋白（a）升高人群的总体心血管风险的建议以及对脂蛋白（a）升高患者的治疗方法的建议。

{"title":"Consensus on lipoprotein(a) of the Spanish Society of Arteriosclerosis. Literature review and recommendations for clinical practice","authors":"Javier Delgado-Lista , Jose M. Mostaza , Teresa Arrobas-Velilla , Francisco Blanco-Vaca , Luis Masana , Juan Pedro-Botet , Pablo Perez-Martinez , Fernando Civeira , Jose I. Cuende-Melero , Jose J. Gomez-Barrado , Carlos Lahoz , Xavier Pintó , Manuel Suarez-Tembra , Jose Lopez-Miranda , Carlos Guijarro","doi":"10.1016/j.artere.2024.07.008","DOIUrl":"10.1016/j.artere.2024.07.008","url":null,"abstract":"<div><p>The irruption of lipoprotein(a) (Lp(a)) in the study of cardiovascular risk factors is perhaps, together with the discovery and use of proprotein convertase subtilisin/kexin type 9 (iPCSK9) inhibitor drugs, the greatest novelty in the field for decades. Lp(a) concentration (especially very high levels) has an undeniable association with certain cardiovascular complications, such as atherosclerotic vascular disease (AVD) and aortic stenosis. However, there are several current limitations to both establishing epidemiological associations and specific pharmacological treatment. Firstly, the measurement of Lp(a) is highly dependent on the test used, mainly because of the characteristics of the molecule. Secondly, Lp(a) concentration is more than 80% genetically determined, so that, unlike other cardiovascular risk factors, it cannot be regulated by lifestyle changes. Finally, although there are many promising clinical trials with specific drugs to reduce Lp(a), currently only iPCSK9 (limited for use because of its cost) significantly reduces Lp(a).</p><p>However, and in line with other scientific societies, the SEA considers that, with the aim of increasing knowledge about the contribution of Lp(a) to cardiovascular risk, it is relevant to produce a document containing the current status of the subject, recommendations for the control of global cardiovascular risk in people with elevated Lp(a) and recommendations on the therapeutic approach to patients with elevated Lp(a).</p></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"36 4","pages":"Pages 243-266"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141954265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of carotid atheroma plaque with IL-18 levels and with polymorphisms in the IL-18 receptor gene in a Mediterranean population 地中海地区人群中颈动脉粥样斑块与 IL-18 水平及 IL-18 受体基因多态性的关系

Clínica e Investigación en Arteriosclerosis (English Edition)

Pub Date : 2024-07-01 DOI: 10.1016/j.artere.2024.07.001

Ana Palanca , Amparo Bartual-Rodrigo , Carolina Cuenca , Oscar D. Mayo-López , F. Javier Ampudia-Blasco , Herminia González-Navarro , Juan F. Ascaso , Ana Bárbara García-García , F. Javier Chaves , José T. Real , Sergio Martínez-Hervás

Background

Atherosclerosis is an inflammatory disease. Interleukin 18 (IL-18) is an inflammatory molecule that has been linked to the development of atherosclerosis and cardiovascular disease.

Objective

To evaluate the possible relationship between plasma levels of IL-18 and the presence of atherosclerosis evaluated at the carotid level, as well as to analyze the possible modulation by different polymorphisms in a Mediterranean population.

Material and methods

746 individuals from the metropolitan area of Valencia were included, recruited over a period of 2 years. Hydrocarbon and lipid metabolism parameters were determined using standard methodology and IL-18 using ELISA. In addition, carotid ultrasound was performed and the genotype of 4 SNPs related to the IL-18 signaling pathway was analyzed.

Results

Patients with higher plasma levels of IL-18 had other associated cardiovascular risk factors. Elevated IL-18 levels were significantly associated with higher carotid IMT and the presence of atheromatous plaques. The genotype with the A allele of the SNP rs2287037 was associated with a higher prevalence of carotid atheromatous plaque. On the contrary, the genotype with the C allele of the SNP rs2293224 was associated with a lower prevalence of atheromatous plaque.

Conclusions

High levels of IL-18 were significantly associated with a higher carotid IMT and the presence of atheromatous plaques, which appear to be influenced by genetic factors, as evidenced by associations between SNPs in the IL-18 receptor gene and the presence of atheroma plaque.

背景动脉粥样硬化是一种炎症性疾病。目的评估血浆中 IL-18 水平与颈动脉粥样硬化之间可能存在的关系，并分析地中海地区人群中不同多态性可能产生的调节作用。采用标准方法测定碳氢化合物和脂质代谢参数，采用 ELISA 方法测定 IL-18。此外，还进行了颈动脉超声检查，并分析了与 IL-18 信号通路相关的 4 个 SNPs 的基因型。IL-18水平升高与颈动脉内中膜厚度升高和动脉粥样斑块的存在明显相关。带有 SNP rs2287037 的 A 等位基因的基因型与较高的颈动脉粥样斑块发病率相关。结论高水平的 IL-18 与较高的颈动脉内中膜厚度和动脉粥样斑块的存在显著相关，这似乎受到遗传因素的影响，IL-18 受体基因中的 SNP 与动脉粥样斑块的存在之间的关联就证明了这一点。

{"title":"Association of carotid atheroma plaque with IL-18 levels and with polymorphisms in the IL-18 receptor gene in a Mediterranean population","authors":"Ana Palanca , Amparo Bartual-Rodrigo , Carolina Cuenca , Oscar D. Mayo-López , F. Javier Ampudia-Blasco , Herminia González-Navarro , Juan F. Ascaso , Ana Bárbara García-García , F. Javier Chaves , José T. Real , Sergio Martínez-Hervás","doi":"10.1016/j.artere.2024.07.001","DOIUrl":"10.1016/j.artere.2024.07.001","url":null,"abstract":"<div><h3>Background</h3><p>Atherosclerosis is an inflammatory disease. Interleukin 18 (IL-18) is an inflammatory molecule that has been linked to the development of atherosclerosis and cardiovascular disease.</p></div><div><h3>Objective</h3><p>To evaluate the possible relationship between plasma levels of IL-18 and the presence of atherosclerosis evaluated at the carotid level, as well as to analyze the possible modulation by different polymorphisms in a Mediterranean population.</p></div><div><h3>Material and methods</h3><p>746 individuals from the metropolitan area of Valencia were included, recruited over a period of 2 years. Hydrocarbon and lipid metabolism parameters were determined using standard methodology and IL-18 using ELISA. In addition, carotid ultrasound was performed and the genotype of 4 SNPs related to the IL-18 signaling pathway was analyzed.</p></div><div><h3>Results</h3><p>Patients with higher plasma levels of IL-18 had other associated cardiovascular risk factors. Elevated IL-18 levels were significantly associated with higher carotid IMT and the presence of atheromatous plaques. The genotype with the A allele of the SNP rs2287037 was associated with a higher prevalence of carotid atheromatous plaque. On the contrary, the genotype with the C allele of the SNP rs2293224 was associated with a lower prevalence of atheromatous plaque.</p></div><div><h3>Conclusions</h3><p>High levels of IL-18 were significantly associated with a higher carotid IMT and the presence of atheromatous plaques, which appear to be influenced by genetic factors, as evidenced by associations between SNPs in the IL-18 receptor gene and the presence of atheroma plaque.</p></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"36 4","pages":"Pages 210-217"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141712627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prof. Rafael Carmena Rodríguez 拉斐尔-卡梅纳-罗德里格斯教授

Clínica e Investigación en Arteriosclerosis (English Edition)

Pub Date : 2024-07-01 DOI: 10.1016/j.artere.2024.07.006

Juan F Ascaso

引用次数: 0